• Vertex Pharmaceuticals
  •  Overview
  • Last Modified:
  • July 22, 2025
  • Company type:
  • Public
  • Industry:
  • Pharmaceutical
  • Verified:
  • No
  • No of Employees:
  • 1 001 - 10 000
  • Stock Code:
  • VRTX
  • Download
  • Signed Health Status Declaration Form
  • Turnover $50m + ?:
  • Yes
  • Headquarters:
  • Boston, Massachusetts, United States
  • Public Interest Score:
  • 750+

 

  • Vertex Pharmaceuticals
  • General Information

Description

Vertex Pharmaceuticals is a leading biotechnology company founded in 1989 and headquartered in Boston, Massachusetts. Known primarily for its groundbreaking treatments for cystic fibrosis (CF), Vertex has developed blockbuster drugs like Trikafta/Kaftrio, which now serve around 90% of CF patients globally. In 2025, the company launched Alyftrek®, a next-generation, once-daily CF therapy. Beyond CF, Vertex is expanding its pipeline into high-impact areas such as gene editing, pain management, and autoimmune diseases. Notable innovations include CASGEVY, the first FDA-approved CRISPR-based therapy for sickle cell disease, and JOURNAVX™, a non-opioid painkiller offering a safer alternative to traditional opioids.

Jeffrey Leiden:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: Yes, qsix: No
Reshma Kewalramani:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: Yes
Sangeeta Bhatia:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Lloyd Carney:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Alan Garber:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Michel Lagarde:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Diana McKenzie:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Bruce Sachs:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: Yes, qsix: No
Jennifer Schneider:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Nancy Thornberry:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Suketu Upadhyay:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No

Subsribe/ Login to view details on company risk rating

Subscribe / Login

 

5 Benchmark > 4 Excellent > 3  Good > 2 Caution > 1 Risk

 

  • Company Information
  • Company System Number:
  • 15669
  • Founded Year: 
  • 1989
  • Registration Number: 
  • 04-3039129
  • Country: 
  • United States of America
  • Stock Exchanges: 
    • NASDAQ Stock Exchange
  • Financial year end: 
  • December
  • No. of Countries operations: 
  • 13
  • Company Status: 
  • In Business
  • Industry Sub Category: 
  • Health Care
  • Date listed on Stock Exchange: 
  • 24/07/1991

 

  • Contact Information
  • Business operation: 
  • We have research and development sites and commercial offices around the world, all dedicated to bringing the next transformative treatments to people with serious diseases
  • Primary office: 
  • 50 Northern Ave, United States

 

  • Additional Information
  • Listed?: 
  • Yes
  • Company secretary: 
  • Joy Liu
  • Reporting currency: 
  • USD
  • ISIN number (12 digit): 
NASDAQ
US92532F1003
  • Authorised shares:
  • 500 000 000
  • Issued shares:
  • 257 011 628
  • No of shareholders:
  • 1001 and more shareholders
  • No of shareholders holding 20%:
  • 0 shareholders
  • Number of shares traded
  • Per Year:
  • Per Quarter:
  • Per Month:

 

Subscribe/ Login to view more details on Health Status 

Subscribe / Login

 

Shareholders holding 5% +


For a comprehensive list, please contact InsidEntity.

Material Subsidiaries/Associates


For a comprehensive list, please contact InsidEntity.

Credit Rating

NameLogoCountryHeadquartersRating
Fitch Credit LogoUnited States of AmericaNew York BBB-

 

Countries Operations/ Offices


 

Company Directors

Name
Nationality
Age
Role
Qualification
Name

Jeffrey

Executive
NationalityAmerican
70
RoleExecutive Chairman
QualificationPhD
Date Appointed: 01/05/2012
Duration:
14 years and 4 months
Independance: N
Profile
Name

Reshma

Executive
NationalityIndia
53
RoleCEO
QualificationM.D
Date Appointed: 01/04/2020
Duration:
6 years and 5 months
Independance: Y
Profile
Name

Sangeeta

Non Executive
NationalityAmerican
58
RoleDirector
QualificationSc.B, S.M, PhD, M.D
Date Appointed: 01/01/2015
Duration:
11 years and 8 months
Independance: N
Profile
Name

Lloyd

Non Executive
NationalityJamaica
64
RoleDirector
QualificationBSEE, MS, PhD
Date Appointed: 01/01/2019
Duration:
7 years and 8 months
Independance: Y
Profile
Name

Alan

Non Executive
NationalityAmerican
71
RoleDirector
QualificationAB, MA, PhD, MD
Date Appointed: 01/01/2017
Duration:
9 years and 8 months
Independance: Y
Profile
Name

Michel

Non Executive
NationalityAmerican
51
RoleDirector
QualificationBAA, EMFC
Date Appointed: 01/01/2023
Duration:
3 years and 8 months
Independance: Y
Profile
Name

Diana

Non Executive
NationalityAmerican
61
RoleNED
QualificationBS & Information Technology
Date Appointed: 01/01/2020
Duration:
6 years and 8 months
Independance: Y
Profile
Name

Bruce

Non Executive
NationalityAmerican
66
RoleNED
QualificationBSEE, MEE, MBA
Date Appointed: 01/01/1998
Duration:
28 years and 8 months
Independance: N
Profile
Name

Jennifer

Non Executive
NationalityAmerican
RoleNED
QualificationM.D., M.S.
Date Appointed: 01/01/2024
Duration:
2 years and 8 months
Independance: Y
Profile
Name

Nancy

Non Executive
NationalityAmerican
RoleNED
QualificationBachelor of Science degree in chemistry and biology
Date Appointed: 01/01/2023
Duration:
3 years and 8 months
Independance: Y
Profile
Name

Suketu

Non Executive
NationalityAmerican
57
RoleDirector
QualificationBFin, MBA, CPA
Date Appointed: 01/01/2022
Duration:
4 years and 8 months
Independance: Y
Profile

 

Directors Tenure

Name
Duration
Name

Jeffrey Leiden

Duration14 years and 4 months
Profile
Name

Reshma Kewalramani

Duration6 years and 5 months
Profile
Name

Sangeeta Bhatia

Duration11 years and 8 months
Profile
Name

Lloyd Carney

Duration7 years and 8 months
Profile
Name

Alan Garber

Duration9 years and 8 months
Profile
Name

Michel Lagarde

Duration3 years and 8 months
Profile
Name

Diana McKenzie

Duration6 years and 8 months
Profile
Name

Bruce Sachs

Duration28 years and 8 months
Profile
Name

Jennifer Schneider

Duration2 years and 8 months
Profile
Name

Nancy Thornberry

Duration3 years and 8 months
Profile
Name

Suketu Upadhyay

Duration4 years and 8 months
Profile

 

Director Experience

Name
Experience
Name

Jeffrey

Experience Medical Equipment, Education, Pharmaceutical
Profile
Name

Reshma

Experience Medical Equipment, Healthcare, Pharmaceutical
Profile
Name

Sangeeta

Experience Medical Equipment, Education, Pharmaceutical
Profile
Name

Lloyd

Experience Technology, Software and IT, Pharmaceutical
Profile
Name

Alan

Experience Pharmaceutical
Profile
Name

Michel

Experience Technology, Pharmaceutical
Profile
Name

Diana

Experience Logistics, Pharmaceutical, Technology
Profile
Name

Bruce

Experience Telecom, Pharmaceutical
Profile
Name

Jennifer

Experience Pharmaceutical, Healthcare
Profile
Name

Nancy

Experience Technology, Chemicals
Profile
Name

Suketu

Experience Financial Services, Business Services
Profile

 

Company Auditors

Name
Date Appointed
Years
Name

Ernst & Young

Date Appointed01/01/2005
Year21 years and 8 months
Profile

 

 

Company Committees

Name

Jeffrey Leiden

Mainboard, Audit, Remuneration BD
Profile
Name

Reshma Kewalramani

Mainboard, Audit, Remuneration BD
Profile
Name

Sangeeta Bhatia

Mainboard, Audit, Remuneration BD, NG, TE
Profile
Name

Lloyd Carney

Mainboard, Audit, Remuneration BD, RE, NG
Profile
Name

Alan Garber

Mainboard, Audit, Remuneration BD, AU, TE
Profile
Name

Michel Lagarde

Mainboard, Audit, Remuneration BD
Profile
Name

Diana McKenzie

Mainboard, Audit, Remuneration BD
Profile
Name

Bruce Sachs

Mainboard, Audit, Remuneration BD, RE, NG
Profile
Name

Jennifer Schneider

Mainboard, Audit, Remuneration BD
Profile
Name

Nancy Thornberry

Mainboard, Audit, Remuneration BD
Profile
Name

Suketu Upadhyay

Mainboard, Audit, Remuneration BD, AU
Profile

 

Committee
Abbreviation
Supervisory Board
SB
Board
BD
Risk & Compliance
RC
Audit
AU
Remuneration
RE
Capital investment
CI
Industry Specific
IS
Nominations & Governance
NG
Health, Safety & Environment
HS
Social & Ethics
SE
Technology
TE
Executive
EX
Other
OT